The Technical Analyst
Orphazyme A/S [ORPH]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Orphazyme A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.870
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/19 | 2/19 | 4/19 | 2/20 | 4/20 | 2/21 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.227 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -0.227 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.713 - 1.027 ( +/- 18.05%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2005-04-18 | Orbimed Advisors Llc | Buy | 0 | Not reporting securities information. |
| 2004-06-30 | Stahl Pamela J | Buy | 17 500 | Stock Option (Right to Buy) |
| 2004-06-15 | Champsi Farah | Buy | 5 000 | Non-employee Director Stock Options (Right to Buy) |
| 2004-06-15 | Vida Julius A | Buy | 5 000 | Non-employee Director Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 3 transactions |
| Buy: 27 500 | Sell: 0 |
Forecast:
01:40 - $0.704
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.870 (0.00% ) |
| Volume | 0.941 mill |
| Avg. Vol. | 1.379 mill |
| % of Avg. Vol | 68.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ORPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ORPH
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Latest Press Releases
2023-04-25 16:20:00 - Press Release
Orphazyme Announces Publication Of 2022 Financial Results And Annual Report
Company announcement
2022-09-26 11:25:00 - Press Release
Orphazyme Reports Financial Results In Interim Report First Half 2022
Company announcement orphazyme a/s no. 36/2022 www.orphazyme.com company registration no. 32266355
2022-06-07 17:34:00 - Press Release
Orphazyme Announces Publication Of 2021 Financial Results And Annual Report
Orphazyme a/scompany announcement no. 30/2022 annual reportwww.orphazyme.com company registration no. 32266355
2022-05-31 12:57:00 - Press Release
Orphazyme Completes Sale Of Substantially All Of Its Assets And Business Activities To Kempharm
Orphazyme a/scompany announcement no. 29/2022 inside information www.orphazyme.com company registration no. 32266355
2022-05-15 17:00:00 - Press Release
Orphazyme A/s Under In-court-restructuring To Sell Substantially All Of Its Assets And Business Activities To Kempharm, Inc.
Orphazyme a/s in restructuring company announcement no. 24/2022inside information www.orphazyme.com company registration no. 32266355
Latest News
2022-03-22 12:30:07 - Benzinga
Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs
Orphazyme A/S (NASDAQ: ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for later this month. "Today's decision to withdraw the MAA enables us to.
2022-03-22 11:20:24 - InvestorPlace
Dear ORPH Stock Fans, Mark Your Calendars for March 31
After Orphazyme announced that it would withdraw the application for approval of its drug and delist its ADSs, ORPH stock is falling. The post Dear ORPH Stock Fans, Mark Your Calendars for March 31 appeared first on InvestorPlace.
2022-03-11 10:42:00 - Benzinga
Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce
Orphazyme A/S's (NASDAQ: ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less than a year. The in-court restructuring will determine whether any operations can continue if the Company can raise any capital or if it is.
2022-02-24 06:41:00 - Benzinga
EMA's Advisory Committee Does Not Back Orphazyme's Arimoclomol Application
Orphazyme A/S (NASDAQ: ORPH) has been notified by the Committee for Medicinal Products for Human Use (CHMP) of a negative trend vote on arimoclomol application following an Oral Explanation. The application covers arimoclomol for Niemann-Pick disease type C (NPC), a rare genetic.
2022-02-14 13:56:08 - Zacks Investment Research
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
2022-02-11 09:14:45 - PennyStocks
Trading Penny Stocks? Top Stock Market News for February 11th, 2022
What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 11th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-02-07 06:22:00 - GlobeNewsWire
Orphazyme to present additional data on arimoclomol's mechanism of action during 2022 Annual WORLDSymposium™
Orphazyme A/S Investor News No. 01/2022 www.orphazyme.com Company Registration No. 32266355
2022-01-19 09:21:55 - PennyStocks
What's Going On in the Stock Market Today, January 19th, 2022
What you need to know about trading penny stocks today The post What's Going On in the Stock Market Today, January 19th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-19 06:18:29 - Benzinga
Orphazyme Tightens FY21 Revenue Outlook
Orphazyme A/S (NASDAQ: ORPH) expects FY21 sales of DKK 35 million – DKK 37 million, compared to the previous guidance of DKK 30 million – DKK 40 million. It anticipates operating expenses of DKK 665 million – DKK 675 million, lower than the earlier outlook of DKK 700 million – DKK 720 million.
2021-11-07 11:30:00 - PennyStocks
Hot Penny Stocks to Buy Right Now? 3 to Watch Next Week
Which penny stocks are on your November watchlist? The post Hot Penny Stocks to Buy Right Now?